184 related articles for article (PubMed ID: 35620025)
1. Assessing quality of life in patients with autoimmune bullous diseases using the Persian version of Treatment of Autoimmune Bullous Disease Quality of Life questionnaire finds similar effects in women as men.
Behkar A; Garmaroudi G; Nasimi M; Yousefi S; Khosravi H; Kianfar N; Murrell DF; Daneshpazhooh M
Int J Womens Dermatol; 2022 Mar; 8(1):e004. PubMed ID: 35620025
[TBL] [Abstract][Full Text] [Related]
2. Measuring of quality of life in autoimmune blistering disorders in Poland. Validation of disease - specific Autoimmune Bullous Disease Quality of Life (ABQOL) and the Treatment Autoimmune Bullous Disease Quality of Life (TABQOL) questionnaires.
Kalinska-Bienias A; Jakubowska B; Kowalewski C; Murrell DF; Wozniak K
Adv Med Sci; 2017 Mar; 62(1):92-96. PubMed ID: 28208086
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the quality of life of Egyptian and Tunisian autoimmune bullous diseases' patients using an Arabic version of the autoimmune bullous disease quality of life and the treatment of autoimmune bullous disease quality of life questionnaires.
Saleh MA; Zaraa I; Doss N; Saleh NA; Murrell DF
An Bras Dermatol; 2019; 94(4):399-404. PubMed ID: 31644610
[TBL] [Abstract][Full Text] [Related]
4. Outcome measures for autoimmune blistering diseases.
Zhao CY; Murrell DF
J Dermatol; 2015 Jan; 42(1):31-6. PubMed ID: 25558950
[TBL] [Abstract][Full Text] [Related]
5. The development and validation of the treatment of autoimmune bullous disease quality of life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering disease.
Tjokrowidjaja A; Daniel BS; Frew JW; Sebaratnam DF; Hanna AM; Chee S; Dermawan A; Wang CQ; Lim C; Venugopal SS; Rhodes LM; Welsh B; Nijsten T; Murrell DF
Br J Dermatol; 2013 Nov; 169(5):1000-6. PubMed ID: 24102329
[TBL] [Abstract][Full Text] [Related]
6. Skin-Related Quality of Life During Autoimmune Bullous Disease Course.
Hopkins ZH; Jimenez A; Taliercio VL; Clarke JT; Hansen CB; Hull CM; Rhoads JLW; Zone JJ; Sahni VN; Kean J; Secrest AM
JAMA Dermatol; 2023 Nov; 159(11):1185-1194. PubMed ID: 37703003
[TBL] [Abstract][Full Text] [Related]
7. The effect of autoimmune blistering diseases on work productivity.
Wang EQ; Radjenovic M; Castrillón MA; Feng GHY; Murrell DF
J Eur Acad Dermatol Venereol; 2018 Nov; 32(11):1959-1966. PubMed ID: 29730897
[TBL] [Abstract][Full Text] [Related]
8. Clinical manifestations of alopecia in autoimmune blistering diseases: A cross-sectional study.
Xie D; Bilgic A; Abu Alrub N; Dicle Ö; Murrell DF
JAAD Int; 2023 Mar; 10():6-13. PubMed ID: 36387063
[TBL] [Abstract][Full Text] [Related]
9. Autoimmune Bullous Disease Quality of Life (ABQoL) questionnaire: Validation of the translated Persian version in pemphigus vulgaris.
Teimourpour A; Hedayat K; Salarvand F; Ghandi N; Ghiasi M; Mahmoudi H; Balighi K; Toosi R; Mohebi F; Nili A; Daneshpazhooh M; Murrell DF; Chams-Davatchi C
Int J Womens Dermatol; 2020 Sep; 6(4):306-310. PubMed ID: 33015292
[TBL] [Abstract][Full Text] [Related]
10. Reliability of the autoimmune bullous disease quality of life (ABQOL) questionnaire in the USA.
Sebaratnam DF; Okawa J; Payne A; Murrell DF; Werth VP
Qual Life Res; 2015 Sep; 24(9):2257-60. PubMed ID: 25795375
[TBL] [Abstract][Full Text] [Related]
11. Rituximab in the Management of Autoimmune Bullous Diseases: A Treatment-Resistant Case Series from a Single Central European Referral Center.
Spałek MM; Jałowska M; Bowszyc-Dmochowska M; Dmochowski M
Medicina (Kaunas); 2024 Feb; 60(2):. PubMed ID: 38399557
[No Abstract] [Full Text] [Related]
12. The pathogeneses of pemphigus and pemphigoid diseases.
Ujiie H; Yamagami J; Takahashi H; Izumi K; Iwata H; Wang G; Sawamura D; Amagai M; Zillikens D
J Dermatol Sci; 2021 Dec; 104(3):154-163. PubMed ID: 34916040
[TBL] [Abstract][Full Text] [Related]
13. Blistering diseases in the mature patient.
Lakoš Jukić I; Jerković Gulin S; Marinović B
Clin Dermatol; 2018; 36(2):231-238. PubMed ID: 29566927
[TBL] [Abstract][Full Text] [Related]
14. [Modern diagnostics of autoimmune bullous diseases].
van Beek N; Schumacher N; Rose C; Schmidt E; Zillikens D
Pathologe; 2020 Jul; 41(4):317-325. PubMed ID: 32542511
[TBL] [Abstract][Full Text] [Related]
15. Oral health related qualıty of lıfe and dısease severıty ın autoımmune bullous dıseases.
Bilgic A; Aydin F; Sumer P; Keskiner I; Koc S; Bozkurt S; Mumcu G; Alpsoy E; Uzun S; Akman-Karakas A
Niger J Clin Pract; 2020 Feb; 23(2):159-164. PubMed ID: 32031089
[TBL] [Abstract][Full Text] [Related]
16. [Bullous autoimmune dermatoses of the mucous membranes].
Didona D; Hinterseher J; Eming R
Dermatologie (Heidelb); 2022 Sep; 73(9):692-700. PubMed ID: 36006424
[TBL] [Abstract][Full Text] [Related]
17. Development of a quality-of-life instrument for autoimmune bullous disease: the Autoimmune Bullous Disease Quality of Life questionnaire.
Sebaratnam DF; Hanna AM; Chee SN; Frew JW; Venugopal SS; Daniel BS; Martin LK; Rhodes LM; Tan JC; Wang CQ; Welsh B; Nijsten T; Murrell DF
JAMA Dermatol; 2013 Oct; 149(10):1186-91. PubMed ID: 23925444
[TBL] [Abstract][Full Text] [Related]
18. The association of six autoimmune bullous diseases with thyroid disorders: a population-based study.
Kridin K; Hübner F; Linder R; Schmidt E
J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):1826-1830. PubMed ID: 35611551
[TBL] [Abstract][Full Text] [Related]
19. The Immunogenetics of Autoimmune Blistering Diseases.
Kneiber D; Kowalski EH; Amber KT
Adv Exp Med Biol; 2022; 1367():173-212. PubMed ID: 35286697
[TBL] [Abstract][Full Text] [Related]
20. New Onset and Exacerbation of Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Systematic Review.
Wu PC; Huang IH; Wang CY; Chi CC
Vaccines (Basel); 2024 Apr; 12(5):. PubMed ID: 38793716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
